Thrive Earlier Detection, headquartered in Cambridge, Massachusetts, closed on a Series B financing worth $257 million.
South San Francisco-based Akero Therapeutics presented results from a 16-week analysis of secondary and exploratory endpoints in the company’s Phase IIa BALANCED clinical trial of efruxifermin in nonalcoholic steatohepatitis (NASH).
Cambridge, Massachusetts-based Thrive Earlier Detection released data from the DETECT-A study evaluating the company’s blood test to screen for multiple types of cancers. The study was run by Johns Hopkins University and Geisinger Health, testing more than 10,000 women with no previous history of cancer.
Business updates for various pharma and life science companies around the globe.
What if you could detect cancer just as it is getting started? New research published in the journal Nature just might give medicine the tools to do just that.
CymaBay Therapeutics Inc. is scrapping two mid-stage trials of the liver disease drug seladelpar after biopsies found a type of liver damage in some patients, sending the company’s shares down more than 75 percent.
Researchers at the University of Strathclyde in Glasgow, Scotland, potentially developed a blood test for brain cancer using high-throughput attenuated total reflection (ATR)-Fourier transform infrared (FTIR) spectroscopy with machine learning.
Thrive Earlier Detection Corp., a liquid biopsy company, raised $110 million in Series A funding.
Researchers at Indiana University developed a blood test that could help more accurately diagnose post-traumatic stress disorder.
Personal Genome Diagnostics Inc. reported that the cancer genomics company’s 500+ gene pan-cancer tumor profiling tissue assay is being used in Merck’s Phase 2 precision oncology KeyImPaCT study of biomarker-directed, pembrolizumab-based combination therapy for advanced non-small-cell lung cancer (KEYNOTE-495).